What diseases does Ibrutinib treat? How effective is it?
Ibrutinib is a targeted therapy drug mainly used to treat various B-cell malignancies and chronic graft-versus-host disease. Its indications include hematological tumors and immune related diseases.
Malignant tumors of the blood system
(1) Chronic lymphocytic leukemia/small lymphocytic lymphoma: suitable for adult patients, including high-risk patients carrying 17p deletion, designated as an orphan drug indication by the FDA.
(2) Fahrenheit macroglobulinemia: Used to treat this rare lymphoproliferative disorder and also approved as an orphan drug by the FDA.
(3) Mantle cell lymphoma: an indication first approved in 2013 for the treatment of relapsed/refractory patients.
2 immune system diseases
(1) Chronic graft-versus-host disease: suitable for children aged ≥ 1 and adult patients, and should be used after at least one systemic treatment has failed.
3 Mechanisms of Drug Action
(1) By irreversibly inhibiting Bruton tyrosine kinase (BTK), blocking the B cell receptor signaling pathway, and inhibiting malignant B cell proliferation.
(2) Simultaneously, it has the function of regulating the tumor microenvironment and enhancing the anti-tumor immune response.
4 main indications and therapeutic effects
(1) Chronic lymphocytic leukemia: Patients with 17p deficiency have a median progression free survival of 44 months and an overall response rate of 89%.
(2) Fahrenheit macroglobulinemia: The overall response rate of monotherapy is 62%, and the combination of rituximab can reach 92%.
(3) Chronic GVHD: Overall response rate is 67%, with a median duration of response of 16.8 months.
5 Pharmacodynamic characteristics
(1) Peak concentration is reached 1-2 hours after oral administration, and steady-state blood drug concentration is maintained for 24 hours, supporting once daily administration.
(2) Food can increase bioavailability by 2-4 times, but the treatment window does not require strict fasting.
6 Special Population Response
(1) Patients with liver function impairment need to reduce their dosage, as drug exposure can increase by 9.8 times.
(2) The therapeutic effect of elderly patients is comparable to that of young people, but it is necessary to strengthen the monitoring of bleeding and infection.
Disclaimer：《What diseases does Ibrutinib treat? How effective is it?》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！